Charles Brown is a Dermatology physician. ClinicalTrials.gov lists 8 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
719 East Boulevard
Charlotte, NC 28203
Telephone
704-376-9849Provider last certified this registry record 12 Apr 2021.
Clinical trials
- Optimization Post-TAVR to IMprove Activity Levels (OPTIMAL Study)
Sponsor: Johns Hopkins University
- Optimizing Cerebral Autoregulation During Surgery
Sponsor: Johns Hopkins University
- Preoperative Optimization to Improve Functional Status
Sponsor: Johns Hopkins University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
34 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20257 payments
- Janssen Biotech, Inc.Program year20255 payments
- Galderma Laboratories, L.P.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
26.3%Tetracycline-class Drug13.3%Doxycycline Hyclate100%Part D≥16 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor8.3%Valacyclovir100%Part D≥18 patients+ 1 more class in this area
Sensory organs
25.2%Corticosteroid25.2%Clobetasol Propionate100%Part D≥53 patientsDermatology
20.9%Corticosteroid11.2%Triamcinolone Acetonide100%Part D≥20 patientsInterleukin-4 Receptor alpha Antagonist5.4%Dupixent Pen100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Hywel C Williams
University of Nottingham
Mohsen Afarideh, MD, MPH
Mayo Clinic
Brigitte Dréno
Centre National de la Recherche Scientifique
Giovanni Damiani
University of Milan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”